Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabelecleucel in EBV+ PTLD after SOT or HCT
NCT03394365Phase 3Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Dec 2017
- Primary completion
- May 2030
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Therapeutic Vaccines
- Countries
- 9
01
Overview
A Phase 3 trial of tabelecleucel in Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD), sponsored by Pierre Fabre Laboratories. Started Dec 2017; status: recruiting.
02
Drugs
tabelecleucel
03
Conditions
Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD)
Beyond the preview
Go deeper on NCT03394365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394365.